Abstract
We report a case of fatal disseminated aspergillosis in the setting of administration of zanubrutinib, a second‐generation Bruton's tyrosine kinase inhibitor thought to have a lower rate of immunosuppression‐related side effects.
Cite
CITATION STYLE
APA
Walsh, M., Xu, A., Ballas, Z., & Sanchez, R. (2023). Disseminated fungal infection in a patient receiving zanubrutinib. Clinical Case Reports, 11(6). https://doi.org/10.1002/ccr3.7564
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free